AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

by Barry101 | Sep 24, 2019 | Press Release, Uncategorized

Important Milestone to Commercial Launch in Argentina Achieved OCALA, FL / September 24, 2019 / AIM ImmunoTech (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and...

AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

by Barry101 | Sep 19, 2019 | Press Release, Uncategorized

New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns ‘Breakthrough Award’ OCALA, FL / September 19, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat...

AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

by Barry101 | Sep 16, 2019 | Press Release, Uncategorized

OCALA, FL / September 16, 2019 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic...

AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

by Barry101 | Sep 13, 2019 | Press Release, Uncategorized

OCALA, FL / September 13, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic...

AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

by Barry101 | Sep 10, 2019 | Press Release, Uncategorized

OCALA, FL / September 10, 2019 / AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic...

AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol ‘AIM’

by Barry101 | Sep 9, 2019 | Press Release, Uncategorized

OCALA, FL / September 9, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that its name change is now complete, with the company’s new website of www.aimimmuno.com and trading on the NYSE American as ‘AIM.’ The immuno-tech company,...